X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Hardy Diagnostics increases manufacturing to meet demand for COVID-19 related products

Content Team by Content Team
1st May 2020
in Manufacturing, News
Hardy Diagnostics increases manufacturing to meet demand for COVID-19 related products

Hardy Diagnostics, a 100% employee owned, FDA-licensed manufacturer headquartered in Santa Maria, CA, has been exponentially increasing production volume of products needed for testing during the COVID-19 global pandemic. Specifically, Hardy has increased production of Viral Transport Medium (VTM, Cat. No. R99), a product recommended by the CDC for collection and transportation of specimens from patients suspected of a COVID-19 infection.

Hardy has increased production volumes from a few hundred tubes of VTM per week to now nearly 500,000 tubes per week. “The demand has placed incredible burden on our company, but one we are happy to support,” says Jay Hardy, Founder and President of Hardy Diagnostics. “It’s been nothing short of miraculous for us to be able to increase our production volumes so drastically. Every owner here at Hardy is proud to be supplying our American customers with these vital products.”

In addition to manufactured products like VTM, Hardy has opened up multiple supply chains for other difficult to obtain products. These include items such as surgical masks, hand sanitizers, and face shields. By working with international and local partners, Hardy Diagnostics has been receiving a steady supply of products and has been carefully allocating them to their customers. “With demand like this, we partner with our laboratory customers to ensure we understand their specific needs,” says Christopher Catani, Director of Sales and Marketing. “It’s incredibly challenging, because everyone is desperate. We’re doing our best to work closely with our customers to ensure we’re supporting them in every way possible.”

About Hardy Diagnostics:
Hardy Diagnostics is an FDA-licensed manufacturer of medical devices for microbiological testing with an ISO 13485 certified Quality Management System. The company manufactures over 2,700 products for the culture and identification of bacteria and fungi from its California and Ohio manufacturing facilities. Hardy Diagnostics is head-quartered in Santa Maria, California, and services over 10,000 laboratories across the nation. In 2015, the company became 100% employee-owned. The company was founded in 1980 by Jay Hardy, a Clinical Laboratory Scientist from Santa Barbara, California. Hardy Diagnostics maintains nine distribution centers nationwide and exports products to over 80 foreign distributors. Hardy Diagnostics’ mission is to produce and distribute the finest products for the detection of microorganisms and partner with its laboratory customers to diagnose and prevent disease.

Previous Post

FDA Grants Hardy Diagnostics Emergency Use Authorization (EUA) for a Rapid Antibody Test Kit for COVID-19

Next Post

Fujifilm Diosynth Biotechnologies Teams with COVID-19 Therapeutics Accelerator

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Next Post
Fujifilm Diosynth Biotechnologies Teams with COVID-19 Therapeutics Accelerator

Fujifilm Diosynth Biotechnologies Teams with COVID-19 Therapeutics Accelerator

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In